Background and Aims. Sulodexide has been reported to have antiproteinuric and nephroprotective properties. We investigated the effects of long-term low-dose Sulodexide on proteinuria and renal function in patients with chronic kidney disease (CKD) caused by diabetic nephropathy (DN), hypertensive nephropathy (HN) and primary glomerulonephritis (GN).
Material and Methods. 100 patients with CKD received low-dose Sulodexide 50 mg/day for 12 months. Treatment efficacy was evaluated as proteinuria reduction compared to baseline; response was defined as a decline in proteinuria below 0.3 g/d. Renal function evolution was assessed by eGFR variation from baseline.
Results. All patients presented reduction of proteinuria, with global mean value of proteinuria decrease of 0.85 ± 1.34 g/d (p<0.0001). Patients with HN had the highest mean percentage of proteinuria reduction (73±29%) and the lowest mean time period to achieve responder status (6.6±2.4 months), compared to patients with DN (57±29%, 8±2.9 months) and GN (63±24%, 10.7±1.2 months). Renal function as mean eGFR remained stable or improved during the study; significant increase was found only in HN group (3.41 ± 6.38 ml/min/1.73m2, p=0.043). Multivariate regression analysis identified that responder status was significantly associated with gender, baseline eGFR, baseline proteinuria and etiology of CKD. Concomitant administration of ACEIs or/and ARBs did not influence the response to Sulodexide therapy.
Conclusions. Independently of ACEIs or/and ARBs therapy, long-term low-dose Sulodexide is efficient as antiproteinuric and renoprotective therapy in patients with CKD caused by DN, GN and HN. Better response is achieved in patients with lower degree of renal dysfunction.
1. MASOLA V, ZAZA G, GAMBARO G. Sulodexide and glycosaminoglycans in the progression of renal disease. Nephrol Dial Transplant 2014; 29: i74-i79.
2. LAUVER DA, LUCCHESI BR. Sulodexide: a renewed interest in this glycosaminoglycan. Cardiovascular Drug Reviews 2006; 24(3-4): 214-226.
3. LAUVER DA, LUCCHESI BR. Sulodexide: A renewed interest in this glycosaminoglycan. Cardiovascular Drug Reviews 2006; 24(3–4): 214–226. 2
4. MANELLO F, MEDDA V, LIGI D, RAFFETTO JD. Glycosaminoglycan sulodexide inhibition of MMP-9 gelatinase secretion and activity: possible pharmacological role against collagen degradation in vascular chronic diseases. Curr Vasc Pharm 2013; 11: 354-365.
5. BROEKHUIZEN LN, LEMKES BA, MOOIJ HL et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia 2010; 53: 2646–2655.
6. KRISTOVA V, LISKOVA S, SOTNIKOVA R et al. Sulodexide improves endothelial dysfunction in streptozotocin-induced diabetes in rats. Physiol Res 2008; 57: 491–494.
7. COFFEY AK, KARNOVSKY MJ. Heparin inhibits mesangial cell proliferation in habu-venom-induced glomerular injury. Am J Pathol 1985; 120: 248–255.
8. LEWIS EJ, XU X. Abnormal glomerular permeability characteristics in diabetic nephropathy: implications for the therapeutic use of low-molecular weight heparin. Diabetes Care 2008; 31(Suppl 2): S202–S207.
9. CEOL M, GAMBARO G, SAUER U et al. Glycosaminoglycan therapy prevents TGF-beta1 overexpression and pathologic changes in renal tissue of long term diabetic rats. J Am Soc Nephrol 2000; 11: 2324–2336.
10. MASOLA V, ONISTO M, ZAZA G, LUPO A, GAMBARO G. A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Translational Medicine 2012; 10: 213.
11. GADDI A, CICERO AFG, GAMBARO G. Nephroprotective action of glycosaminoglycans: why the pharmacological properties of Sulodexide might be reconsidered. Int J Nephrol Renovasc Dis 2010; 3: 99-105.
12. SOLINI A, CARRARO A, BARZON I et al. Therapy with glycosaminoglycans lowers albumin excretion rate in non-insulin dependent diabetic patients with microalbuminuria. Diab Nutr Metab 1994; 7: 304–307.
13. GAMBARO G, KINALSKA I, OKSA A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric Type 1 and Type 2 diabetic patients: The Di.N.A.S. randomized trial. J Am Soc Nephrol 2002; 13: 1615–1625.
14. BLOUZA S, DAKHLI S, ABID H et al. Efficacy of low-dose oral sulodexide in the management of diabetic nephropathy. J Nephrol 2010; 23: 415–424.
15. ROZITA M, MD SHAHRIR MS, LOO CY et al. Glycosaminoglycans (sulodexide) for resistant heavy proteinuria of chronic glomerulonephritides. Nephrology 2008; 13(Suppl 1): A13.
16. BANG K, CHIN HJ, CHAE DW et al. Anti-proteinuric effect of sulodexide in Immunoglobulin A Nephropathy. Yonsei Med J 2011; 52: 588–594.
17. PALATINI P. Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension. Nephrol Dial Transplant 2012; 27: 1708-1714.
18. CHRISTIANSEN REF, TENSTAD O, LEH S, IVERSEN BM. Glomerular charge selectivity is impaired in hypertensive nephropathy. Nephrol Dial Transplant, 2004; 19: 1083-1091.
19. HEERSPINK HL, GREENE T, LEWIS JB, et al. Collaborative Study Group. Effects of Sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant 2008; 23(6):1946–1954.
20. LI P, MA LL, XIE RJ, et al. Treatment of 5/6 nephrectomy rats with sulodexide: a novel therapy for chronic renal failure. Acta Pharmacologica Sinica 2012; 33: 644–651.